Core Viewpoint - Boston Scientific (BSX) is experiencing growth driven by new product launches and strategic acquisitions, with international expansion being a significant growth driver. The stock is rated as a Zacks Rank 2 (Buy) [1]. Group 1: Factors Driving Growth - Boston Scientific is successfully expanding its operations internationally, particularly in Europe, the Middle East, and Africa (EMEA), where sales grew 8% year over year in Q1 2025, driven by strong performance in electrophysiology (EP) and double-digit growth in key technologies [2]. - The Endoscopy business within MedSurg is benefiting from strong growth in endoluminal surgery and single-use imaging franchises, with positive reimbursement developments for its ESG weight loss procedure [3]. - Recent acquisitions, including Bolt Medical, Cortex, Silk Road, and Axonics, have added numerous products with potential, contributing to an 18.2% organic revenue growth in Q1, with closed acquisitions adding 400 basis points [4]. Group 2: Challenges and Competitive Landscape - Boston Scientific faces a challenging business environment due to macroeconomic pressures, including geopolitical tensions and global supply chain disruptions, with tariffs expected to impact $200 million in 2025 [6]. - The company reported a 20.2% increase in product costs and a 17.1% rise in selling, general, and administrative expenses in Q1 2024, indicating rising operational costs [7]. - The medical devices market is highly competitive, with Boston Scientific competing against well-capitalized companies like Johnson & Johnson, Abbott, and Medtronic, among others [8].

Core Viewpoint - Growth investors are increasingly focused on stocks with above-average financial growth, and Boston Scientific (BSX) is highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10] Earnings Growth - Boston Scientific has a historical EPS growth rate of 17.6%, with projected EPS growth of 15.8% for the current year, surpassing the industry average of 12.5% [4] Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 26.5%, significantly higher than the industry average of -8.8% [5] - Over the past 3-5 years, Boston Scientific's annualized cash flow growth rate has been 9.9%, compared to the industry average of 7.9% [6] Earnings Estimate Revisions - There have been upward revisions in current-year earnings estimates for Boston Scientific, with the Zacks Consensus Estimate increasing by 2.2% over the past month [8]

Core Viewpoint - Boston Scientific (BSX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts, and is crucial for understanding stock price movements [1][2]. - Changes in earnings estimates are strongly correlated with stock price movements, particularly due to institutional investors who adjust their valuations based on these estimates [4][6]. Business Improvement Indicators - The upgrade in Boston Scientific's rating suggests an improvement in the company's underlying business, which is expected to lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Boston Scientific is projected to earn $2.91 per share, reflecting a 15.9% increase from the previous year, with a 5.2% rise in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - The upgrade to Zacks Rank 2 places Boston Scientific in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月23日，波士顿科学 Boston Scientific (NYSE:BSX) 公布2025年第一季度业绩，第一季度总营收达到 46.63亿美元（合约340.1亿人民币） ， 销售额增长 20.9% ，净利润大幅增长 36.2% ，并且上调了其全年业绩指引。 在23日的早盘交易中，波士顿科学股价上涨 超过5% ，达到每股100.28美元，同期标准普尔500指数上涨 超过2% 。 # 财 报 详情 第一季度总体净销售额达到 46.63亿美元 ，按报告增长20.9%；GAAP每股收益为0.45美元， 调整后的每股收益达到0.75美元。 | | Three Months Ended | | | | | | --- | --- | --- | --- | --- | --- | | | March 31, | | | | Reported | | (in millions) | 2025 | | 2024 | | Basis | | Endoscopy | র্ব | 673 | दे | 642 | 4.7 % | | U ...

Financial Data and Key Metrics Changes - In Q1 2025, total company operational sales grew 22% and organic sales grew 18%, exceeding the guidance range of 14% to 16% [10][34] - Adjusted EPS for Q1 was $0.75, a 34% increase, surpassing the guidance range of $0.66 to $0.68 [11][35] - Adjusted operating margin for Q1 was 28.9%, with adjusted gross margin at 71.5%, reflecting a 170 basis point improvement year-over-year [11][35][36] Business Line Data and Key Metrics Changes - Urology sales grew 25% operationally and 4% organically, driven by the core stone franchise [17] - Endoscopy sales increased by 6% both operationally and organically, with strong performance from the Axios platform [18] - Cardiology sales grew 31%, with interventional cardiology therapies sales up 9% [19][20] - Electrophysiology sales surged 145%, establishing the company as the 2 player in the market [24][25] Market Data and Key Metrics Changes - U.S. operational sales grew 31%, with double-digit growth in five of eight business units [13] - Europe, Middle East, and Africa saw 8% operational growth, led by exceptional performance in electrophysiology [14] - Asia Pacific grew 11% operationally, with Japan showing strong uptake of FARAPULSE [15] Company Strategy and Development Direction - The company remains committed to a diversified global manufacturing footprint, with significant investments in the U.S. [12][13] - The acquisition of SoniVie is expected to close in Q2 2025, enhancing the company's portfolio in ultrasound-based renal denervation technology [21][112] - The company aims to continue expanding its leadership in electrophysiology through clinical evidence and innovation [25][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 12% to 14% for the full year, despite a $200 million tariff impact [11][45] - The company anticipates continued strong performance in the cardiology portfolio and expects to offset tariff impacts through sales growth and cost reductions [12][45] - Management highlighted the importance of ongoing investments in clinical trials and product development to support future growth [21][60] Other Important Information - Dan Brennan, the CFO, announced his retirement after 30 years with the company, with John Monson set to succeed him [31][47] - The company received credit rating upgrades to single A- from both Standard & Poor's and Fitch ratings [39] Q&A Session Summary Question: Impact of tariffs on performance - Management confirmed a $200 million tariff headwind for 2025, primarily affecting the second half, and outlined strategies to offset this through revenue performance and discretionary spending reductions [51][53] Question: Market share in electrophysiology - Management expressed ambition to become the 1 player in electrophysiology, supported by strong clinical science and investments in the market [58][60] Question: WATCHMAN franchise growth - Management reported a 24% growth in WATCHMAN sales, driven by strong adoption of concomitant procedures and positive clinical data [64][66] Question: Trade environment and supply chain concerns - Management acknowledged challenges in the trade environment but emphasized the company's ability to absorb tariff impacts and maintain strong performance [74][76] Question: Outlook for CRM division - Management expressed confidence in the CRM division's future, with expected approval of the Empower device in the second half of 2025, which will enhance growth [100][102]

Core Viewpoint - Boston Scientific Corporation (BSX) reported strong first-quarter 2025 results, with adjusted earnings per share (EPS) of 75 cents, a 33.9% increase year-over-year, surpassing both the Zacks Consensus Estimate and the company's own guidance range [1][3][11] Financial Performance - The first-quarter revenue reached $4.66 billion, reflecting a 20.9% year-over-year increase on a reported basis and 22.2% on an operational basis, exceeding the Zacks Consensus Estimate by 2.3% [3][11] - Reported EPS for the quarter was 45 cents, marking a 36.4% increase from the previous year [2] Revenue Breakdown - Revenue growth by region included a 31.1% increase in the United States, 5.5% in EMEA, 8.2% in Asia Pacific, and 4.4% in Latin America and Canada [4] - Emerging markets saw a reported revenue growth of 6.5% [4] Segment Performance - MedSurg segment revenues were $1.58 billion, up 11.7% year-over-year, with notable contributions from Endoscopy ($673 million), Urology ($633 million), and Neuromodulation ($271 million) [6] - Cardiovascular segment revenues reached $3.09 billion, a 26.2% increase, with Cardiology business sales totaling $2.43 billion, up 31.2% [7] Margin Analysis - Gross margin expanded by 19 basis points to 68.8%, while adjusted operating margin increased by 127 basis points to 24.8% [8] Future Outlook - For 2025, BSX anticipates net sales growth of approximately 15-17% on a reported basis and 12-14% on an organic basis, with adjusted EPS expected in the range of $2.87-$2.94 [9][10] - The second quarter of 2025 is projected to see revenue growth of 17.5-19.5% on a reported basis [10] Strategic Developments - Recent acquisitions include SoniVie Ltd. and Bolt Medical, which are expected to positively impact the company's growth trajectory [12]

For the quarter ended March 2025, Boston Scientific (BSX) reported revenue of $4.66 billion, up 20.9% over the same period last year. EPS came in at $0.75, compared to $0.56 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.56 billion, representing a surprise of +2.31%. The company delivered an EPS surprise of +11.94%, with the consensus EPS estimate being $0.67.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

Core Viewpoint - Boston Scientific Corporation announces the retirement of Dan Brennan, the executive vice president and chief financial officer, after nearly 30 years with the company, effective at the end of June 2025, with a transition period as a senior advisor until early October 2025 [1][2] Company Leadership Transition - Jon Monson, currently senior vice president of Investor Relations, will succeed Dan Brennan as executive vice president and CFO, effective June 30, 2025, reporting to CEO Mike Mahoney [2][3] - Brennan and Monson will collaborate closely to ensure a smooth transition, with Monson taking on responsibilities including global controllership, corporate finance, and corporate business development [2][3] Dan Brennan's Contributions - Dan Brennan has been recognized for his exceptional leadership and contributions to Boston Scientific, particularly in transforming the company's financial performance and developing talent within the financial organization [2][3] - Under Brennan's leadership since 2014, the company has overseen numerous strategic investment opportunities [2] Jon Monson's Background - Jon Monson has over 25 years of experience with Boston Scientific, having held various roles in finance, including global controller and chief accounting officer [3] - He is a certified public accountant with a Bachelor of Arts degree in economics and accounting from the College of the Holy Cross [3] Company Overview - Boston Scientific is a global leader in medical technology, providing innovative solutions to improve patient health and reduce healthcare costs [4] - The company has been advancing science for life for over 45 years, offering a wide range of devices and therapies for various medical conditions [4]

Financial Performance - Boston Scientific reported net sales of $4.663 billion for Q1 2025, a 20.9% increase on a reported basis, 22.2% on an operational basis, and 18.2% on an organic basis compared to the prior year[1][3]. - GAAP net income attributable to common stockholders was $674 million, or $0.45 per share, compared to $495 million, or $0.33 per share a year ago; adjusted EPS was $0.75, up from $0.56[1][3]. - Net sales for Q1 2025 reached $4,663 million, a 21% increase from $3,856 million in Q1 2024[21]. - Gross profit for Q1 2025 was $3,210 million, up from $2,648 million in Q1 2024, reflecting a gross margin improvement[21]. - Operating income increased to $921 million in Q1 2025, compared to $675 million in Q1 2024, representing a 36% growth[21]. - Net income attributable to Boston Scientific common stockholders for Q1 2025 was $674 million, a 36% increase from $495 million in Q1 2024[21]. - Basic net income per share for Q1 2025 was $0.46, up from $0.34 in Q1 2024, indicating a 35% increase[21]. - Adjusted net income for Q1 2025 was $1,121 million, compared to $832 million in Q1 2024, reflecting a significant increase[23]. Sales Growth - The Cardiovascular segment achieved a reported sales growth of 26.2%, while MedSurg grew by 11.7% compared to the prior year[3]. - U.S. sales increased by 31.1% to $2.96 billion, while EMEA and APAC regions saw growth of 5.5% and 8.2%, respectively[9]. - Full year 2025 net sales growth is estimated to be approximately 15% to 17% on a reported basis and 12% to 14% on an organic basis[11]. - For Q2 2025, the company expects net sales growth in the range of 17.5% to 19.5% on a reported basis and 13% to 15% on an organic basis[12]. - The company expects Q2 2025 net sales growth to be between 17.5% and 19.5%, with full-year growth estimated at 15.0% to 17.0%[27]. - Organic growth for Q2 2025 is projected to be between 13.0% and 15.0%, and for the full year, it is expected to be between 12.0% and 14.0%[27]. Research and Development - The company plans to continue investing in research and development, with R&D expenses increasing to $443 million in Q1 2025 from $366 million in Q1 2024[21]. Acquisitions and Clinical Trials - Boston Scientific completed the acquisition of Bolt Medical, Inc., and announced an agreement to acquire SoniVie Ltd., focusing on innovative medical technologies[7]. - The company commenced enrollment in the ELEVATE-PF clinical trial for the FARAFLEX™ Mapping and Pulsed Field Ablation Catheter targeting persistent atrial fibrillation[7]. Product Performance - The FARAPULSE™ PFA System demonstrated superior effectiveness in treating symptomatic paroxysmal atrial fibrillation compared to Medtronic's Arctic Front Advance™ catheter[7]. Operational Challenges - Boston Scientific is focusing on operational growth while managing the impact of acquisitions and divestitures, which is expected to affect growth rates negatively by approximately 4.5% in Q2 2025[27].

MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, ...